1. Home
  2. DMRA vs BHVN Comparison

DMRA vs BHVN Comparison

Compare DMRA & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$24.60

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$8.73

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRA
BHVN
Founded
2011
2013
Country
United States
United States
Employees
7
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
DMRA
BHVN
Price
$24.60
$8.73
Analyst Decision
Buy
Buy
Analyst Count
2
14
Target Price
$43.00
$29.08
AVG Volume (30 Days)
279.5K
1.6M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.08
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.50
$7.48
52 Week High
$28.76
$18.57

Technical Indicators

Market Signals
Indicator
DMRA
BHVN
Relative Strength Index (RSI) 48.32 39.06
Support Level $22.71 $8.08
Resistance Level $28.00 $10.57
Average True Range (ATR) 1.84 0.67
MACD -0.13 -0.12
Stochastic Oscillator 52.01 7.24

Price Performance

Historical Comparison
DMRA
BHVN

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Share on Social Networks: